Antiplatelet effects of oral anticoagulants in patients with atrial fibrillation: ex-vivo studies
Journal of Thrombosis and Thrombolysis · 09.07.2026
DOI: 10.1007/s11239-026-03356-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, online erschienen am 09.07.2026. Verfasst von Giulia Renda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Imaging and Clinical Sciences and Center for Advanced Studies and Technology, G. d'Annunzio University Chieti-Pescara, Ch…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Boehringer Ingelheim, Bayer, BMS-Pfizerx.
Abstract (Originalsprache)
The impact of direct oral anticoagulants (DOACs) on platelet function is still unclear. We conducted an observational study aimed at assessing the effect of DOACs on platelet function in patients with atrial fibrillation (AF) treated with the direct thrombin inhibitor dabigatran (n = 22) and the Factor Xa (FXa) inhibitors rivaroxaban (n = 20), apixaban (n = 22) and edoxaban (n = 12), compared with patients treated with the vitamin K antagonist warfarin (n = 26) and with untreated patients without AF as controls (n = 23). We evaluated thrombin generation by calibrated automated thrombogram (CAT); light transmittance platelet aggregation (LTA) induced by adenosine diphosphate (ADP), thrombin, thrombin receptor-activating peptide (TRAP) and tissue factor (TF); serum thromboxane (TX) generation; the expressions of protease-activated receptor (PAR)-1 and P-selectin on the platelet surface. Thrombin generation was reduced in patients treated with FXa inhibitors as well as in patients treated with warfarin compared to controls. Patients treated with rivaroxaban and apixaban showed significantly reduced LTA compared to controls with all used agonists; while patients treated with dabigatran and edoxaban showed reduced thrombin- and TF-induced aggregation, respectively. TXB2 production was reduced only in patients treated with FXa inhibitors. Patients treated with dabigatran and warfarin showed a higher proportion of activated platelets expressing P-selectin, and dabigatran-treated patients showed significantly higher expression of PAR-1 compared with controls. Our study shows that FXa inhibitors appear to have a more marked antiplatelet activity than dabigatran. These findings may be of relevance in differentiating specific effects and in selecting the most appropriate therapy for the individual patient.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Imaging and Clinical Sciences and Center for Advanced Studies and Technology, G. d'Annunzio University Chieti-Pescara, Chieti, Italy.
- Cardiovascular Sciences Department, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- Department of Medicine and Aging Sciences and Center for Advanced Studies and Technology, G. d'Annunzio University Chieti-Pescara, Chieti, Italy.
- Cardiology Unit, National Institute of Health and Science on Aging (INRCA), Ancona, Italy.
- Chair of Cardiology, University of Pisa, Pisa, Italy. raffaele.decaterina@unipi.it.
Förderung
- Boehringer Ingelheim
- Bayer
- BMS-Pfizerx
- Daiichi-Sankyo
Zitieren
APA
Renda, G., Bucciarelli, V., Barbieri, G., Lanuti, P., Berteotti, M., Malatesta, G., Cesari, F., Giusti, B., Gori, A. M., Marcucci, R., & De Caterina, R. (2026). Antiplatelet effects of oral anticoagulants in patients with atrial fibrillation: ex-vivo studies. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-026-03356-7
Vancouver
Renda G, Bucciarelli V, Barbieri G, Lanuti P, Berteotti M, Malatesta G, et al. Antiplatelet effects of oral anticoagulants in patients with atrial fibrillation: ex-vivo studies. Journal of Thrombosis and Thrombolysis. 2026. doi:10.1007/s11239-026-03356-7
BibTeX
@article{Renda2026,
author = {Renda, Giulia and Bucciarelli, Valentina and Barbieri, Giulia and Lanuti, Paola and Berteotti, Martina and Malatesta, Gelsomina and Cesari, Francesca and Giusti, Betti and Gori, Anna Maria and Marcucci, Rossella and De Caterina, Raffaele},
title = {Antiplatelet effects of oral anticoagulants in patients with atrial fibrillation: ex-vivo studies},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2026},
doi = {10.1007/s11239-026-03356-7}
}
EUVIMED